Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis
Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments.
Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?
Bucking Biosimilar Threat, Roche Sees Further Growth
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
Investigating Big Pharma Licensing Trends
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.
AZ, Novartis, Roche Take Part In UK’s Big Data Push
Seven hubs will bring together data sets and help accelerate clinical trials.
Roche Mounts NMOSD Challenge To Alexion’s Soliris
Satralizumab will be boosted by convenience and MS portfolio in increasingly competitive field.